Table 1 Baseline clinical characteristics of subjects who have an sRAGE measurement by cohort
From: Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD
|  | COPDGene (n = 1443) | ECLIPSE (n = 2349) | SCCOR (n = 399) | SPIROMICS (n = 1623) | p-value |
|---|---|---|---|---|---|
Age (mean ± SD) | 61 ± 9 | 62 ± 8 | 65 ± 6 | 64 ± 9 | < 0.001 |
Sex (male) (%) | 49% | 62% | 53% | 54% | < 0.001 |
Race (%) | |||||
 Non-Hispanic White | 86% | 93.5% | 95% | 75% | < 0.001 |
 Non-Hispanic African American | 14% | 1.5% | 4% | 16% | |
 Other | 0% | 5% | 1% | 9% | |
BMI (kg/m2) (mean ± SD) | 29 ± 6 | 27 ± 5 | 28 ± 4 | 28 ± 5 | < 0.001 |
Never Smoker (%) | 2% | 9% | 0% | 8% | < 0.001 |
Current Smoker (%) | 39% | 35% | 42% | 34% | |
Pack-years median (5th and 95th percentile) | 38.4 (11.3; 90.0) | 39 (0; 95) | 46.0 (19.0; 118.0) | 42.0 (0; 96.0) | < 0.001 |
COPD (%) | 41% | 78% | 48% | 62% | < 0.001 |
PRISm (%) | 10% | 0.2% | 5% | 2% | < 0.001 |
FEV1 (% predicted) (mean ± SD) | 81 ± 25 | 62 ± 30 | 83 ± 20 | 76 ± 26 | < 0.001 |
FEV1 (L) (mean ± SD) | 2.36 ± 0.91 | 1.79 ± 1.00 | 2.39 ± 0.76 | 2.15 ± 0.91 | < 0.001 |
FVC (L) (mean ± SD) | 3.44 ± 1.00 | 3.30 ± 1.03 | 3.54 ± 0.89 | 3.44 ± 1.02 | 0.006 |
Emphysema (% LAA < − 950 HU) median (5th and 95th percentile) | 1.40 (0.08; 26.19) | 11.48 (0.49; 39.18) | 0.80 (0.10; 17.40) | 3.07 (0.29; 29.54) | < 0.001 |
PD15adj (g/L) (mean ± SD) | 89 ± 24 | 61 ± 26 | 87 ± 21 | 83 ± 26 | < 0.001 |
History of diabetes (%) | 11% | 9% | 8% | 13% | < 0.001 |
History of heart attack (%) | 6% | 8% | 5% | 6% | 0.009 |
History of coronary artery disease (%) | 7% | NC | 6% | 9% | 0.12 |
History of stroke (%) | 2% | 3% | 3% | 4% | 0.11 |
Follow-up (years) median (5th and 95th percentile) | 5.14 (0; 10.1) | 3.0 (1.5; 3.0) | 6.0 (2.0; 6.0) | 3.1 (0; 7.5) | < 0.001 |
Percentage of visits with a spirometry per participant | |||||
 0 | 0.1% |  |  | 0.1% |  |
 1 | 39% | 0.04% |  | 12% |  |
 2 | 44% | 0.04% | 39% | 12% |  |
 3 | 16% | 1% | 61% | 18% |  |
 4 |  | 4% |  | 34% |  |
 5 |  | 4% |  | 24% |  |
 6 |  | 5% |  |  |  |
 7 |  | 10% |  |  |  |
 8 |  | 76% |  |  |  |
Number of visits with CT scan per participant | |||||
 0 | 1% | 7% |  | 0.1% |  |
 1 | 41% | 11% |  | 13% |  |
 2 | 58% | 21% | 39% | 50% |  |
 3 |  | 61% | 61% | 36% |  |